Table 4. Clinical-pathological breast cancer characteristics and BMI, χ2 test was used to calculate p-value.
| Features | Tot (%) | Low (n = 111) | Medium (n = 115) | High (n = 74) | P-value | |
| Menopausal status | Pre | 34 | 55 (49,5%) | 35 (30,4%) | 13 (17,6%) | <0.0001 |
| Post | 66 | 56 (50,5%) | 80 (69,6%) | 61 (82,4%) | ||
| Tumor size | ≤2 cm | 43 | 60 (56,6%) | 39 (36,1%) | 23 (32,4%) | 0.0013 |
| >2 cm | 57 | 46 (43,4%) | 69 (63,9%) | 48 (67,6%) | ||
| Cytohistological grading | 1 | 9 | 14 (13.5%) | 8 (7.4%) | 2 (3.1%) | 0.0631 |
| 2 | 42 | 43 (41.3%) | 51 (47.2%) | 23 (35.9%) | ||
| 3 | 49 | 47 (45.2%) | 49 (45.4%) | 39 (60.0%) | ||
| Marker Ca15.3 (U/ml) | >40 | 21 | 15 (14.3%) | 18 (16.1%) | 27 (38.1%) | 0.0002 |
| < = 40 | 79 | 90 (85.7%) | 94 (83.9%) | 44 (61.9%) | ||
| Immunohistochemical markers | ER + | 75 | 79 (73,2%) | 88 (80,7%) | 51 (70,8%) | 0.249 |
| ER − | 25 | 29 (26.8%) | 21 (19.3%) | 21 (29.2%) | ||
| PgR + | 60 | 61 (55.9%) | 70 (64.2%) | 43 (59.7%) | 0.4604 | |
| PgR − | 40 | 48 (44.1%) | 39 (35.8%) | 29 (40.3%) | ||
| Mib + | 50 | 59 (54.1%) | 48 (44.1%) | 38 (52.8%) | 0.2843 | |
| Mib − | 50 | 50 (45.9%) | 61 (55.9%) | 34 (47.2%) | ||
| Axillary | Positive | 55 | 43 (40,6%) | 63 (62,4%) | 38 (61,3%) | 0.003 |
| Negative | 45 | 63 (59,4%) | 38 (37,6%) | 24 (38.7%) |